Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-07-13 | Reverse | 1:20 |
| 2025-07-14 | Reverse | 1:20 |
| 2017-07-11 | Reverse | 1:100 |
Beyond Air, Inc. develops the LungFit nitric oxide platform for treating pulmonary hypertension, viral lung infections, and nontuberculous mycobacteria, focusing on medical devices and biopharmaceuticals.

The LungFit PH is an FDA-approved device that produces nitric oxide from ambient air for on-demand delivery to neonates with respiratory failure, replacing bulky cylinders.
| Icon | PRODUCT | Q1-2026 | Q2-2026 | Q4-2026 | Q1-2027 |
|---|---|---|---|---|---|
![]() | Business Segment | $1.76M | $2.12M ▲ | $3.8M ▲ | $1.77M ▼ |
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
CLRB | $2.59 | COMPARE |
LFWD | $7.32 | COMPARE |
TRIB | $10.60 | COMPARE |
SINT | $1.55 | COMPARE |
AEON | $0.19 | COMPARE |
BOLT | $3.67 | COMPARE |
TNON | $6.83 | COMPARE |
CODX | $1.21 | COMPARE |